截至 2023 年 6 月 30 日，公司累计使用募集资金人民币 118,464,377.20 元， 其中微生态制剂产业化项目使用募集资金 102,050,522.20 元，使用募集资金置换 前期以自筹资金投入营销服务中心建设项目 16,413,855.00 元。募集资金均用于 公司已披露的募集资金项目。 | 户名 | 开户行 | 账号 | 余额 | | --- | --- | --- | --- | | 山西大禹生物工程 | 中国邮政储蓄银行 | 914006010003337860 | 13,064,207.61 | | 股份有限公司 | 股份有限公司芮城 | | | | | 县支行 | | | | 山西大禹生物工程 | 山西芮城农村商业 | 654103010300000065690 | 523,644.61 | 证券代码：871970 证券简称：大禹生物 公告编号：2023-062 山西大禹生物工程股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 ...

第三届监事会第八次会议决议公告 证券代码：871970 证券简称：大禹生物 公告编号：2023-058 山西大禹生物工程股份有限公司 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 5.会议主持人：赵一霖 6.召开情况合法、合规、合章程性说明： 本次会议的召开符合《中华人民共和国公司法》、《公司章程》和《监事会议 事规则》的有关规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司 2023 年半年度报告及摘要》议案 1.议案内容： 具体内容详见公司于 2023 年 8 月 28 日在北京证券交易所信息披露平台 （www.bse.cn）上披露的《2023 年半年度报告》（公告编号：2023-060）和《2023 3.回避表决情况 本议案不涉及关联交易事项，无需回避表决。 本议案无需提交股东大会审议。 （二）审议通过《关于公司募集资金存放与实际使用情况的专项报告》议案 1.议案内容： 具体内容详 ...

证券代码：871970 证券简称：大禹生物 公告编号：2023-057 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯 4.发出董事会会议通知的时间和方式：2023 年 8 月 15 日以通讯方式发出 5.会议主持人：闫和平 山西大禹生物工程股份有限公司 第三届董事会第十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 26 日 二、议案审议情况 （一）审议通过《关于公司 2023 年半年度报告及摘要》的议案 1.议案内容： 具体内容详见公司于 2023 年 8 月 28 日在北京证券交易所信息披露平台 （www.bse.cn）上披露的《2023 年半年度报告》（公告编号：2023-060）和《2023 年半年度报告摘要》（公告编号：2023-061）。 2.议案表决结果：同意 7 票；反对 0 票；弃权 0 票。 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本 ...

山西大禹生物工程股份有限公司 独立董事关于第三届董事会第十次会议相关事项的独立意见 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 山西大禹生物工程股份有限公司（以下简称"公司"）于 2023 年 8 月 26 日 召开第三届董事会第十次会议，根据《公司法》《公司章程》以及《独立董事工 作制度》等有关规定，我们作为公司独立董事，现基于独立判断，就公司该次会 议的相关事项发表独立意见如下： 证券代码：871970 证券简称：大禹生物 公告编号：2023-059 一、《关于募集资金存放与实际使用情况的专项报告的议案》的独立意见 经审阅，我们认为：《募集资金存放与实际使用情况的专项报告》真实、准 确、完整地反映了公司 2023 年半年度募集资金实际存放与使用情况。公司募集 资金的存放与实际使用符合《北京证券交易所股票上市规则（试行）》等相关法 律法规和规范性文件以及《公司章程》《募集资金管理办法》等公司制度的规定， 不存在违规存放与使用募集资金及损害公司和全体股东利益的情形。 综上，我们同意此议案。 山西大禹 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥69,247,737.67, representing a 16.58% increase compared to ¥59,399,772.91 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was -¥6,067,336.80, a decrease of 177.35% from ¥7,844,216.36 in the previous year[26]. - The gross profit margin dropped to 26.00% from 50.09% year-on-year[26]. - The company's total revenue for the reporting period was 69.25 million yuan, representing a year-on-year increase of 16.58%[36]. - The net profit attributable to shareholders was -6.07 million yuan, a decline of 177.35% compared to the same period last year[36]. - The company reported a net non-recurring profit of 2.50 million yuan after tax, with total non-recurring gains amounting to 2.94 million yuan[31]. - The total profit for the first half of 2023 was a loss of CNY 5,413,666.27, compared to a profit of CNY 10,016,215.36 in the same period of 2022[124]. Assets and Liabilities - Total assets at the end of the reporting period were ¥424,819,095.73, a decrease of 1.96% from ¥433,317,187.05 at the end of the previous year[27]. - Total liabilities increased by 48.38% to ¥111,488,155.19 from ¥75,138,629.71 year-on-year[27]. - The net asset attributable to shareholders of the listed company decreased by 12.52% to ¥313,330,940.54 from ¥358,178,557.34[27]. - Total liabilities amounted to ¥111,488,155.19, up from ¥75,138,629.71, reflecting a significant increase[114]. - The company reported a total current assets of ¥79,720,700.36 as of June 30, 2023, down from ¥105,123,933.33 at the end of 2022, representing a decrease of approximately 24.2%[112]. - The company’s cash and cash equivalents decreased to ¥21,339,825.48 from ¥45,112,911.72, a decline of approximately 52.7%[112]. - The company’s accounts receivable decreased from ¥20,901,640.10 to ¥18,102,220.52, a reduction of approximately 13.4%[112]. - The company’s inventory remained relatively stable, with a slight decrease from ¥33,751,160.28 to ¥33,515,851.53, a change of about 0.7%[112]. Cash Flow - The company's cash flow from operating activities was ¥2,365,660.95, an increase of 11.99% compared to ¥2,112,318.87 in the previous year[28]. - Net cash flow from operating activities increased by 11.99% to 2,365,660.95 CNY, while net cash flow from financing activities decreased by 97.10% to 3,369,378.31 CNY[59][60]. - Cash inflow from operating activities for the first half of 2023 was CNY 86,296,181.87, an increase of 22% compared to CNY 70,761,385.05 in the same period of 2022[127]. - Total cash inflow from financing activities was CNY 103,000,000.00, significantly higher than CNY 45,000,000.00 in the previous year, indicating a growth of 129%[128]. - Cash outflow for purchasing goods and services increased to CNY 47,116,620.59, compared to CNY 35,882,026.99 in the first half of 2022, marking a rise of 31%[127]. Shareholder Information - The company distributed a total cash dividend of ¥38,780,280.00 to shareholders, increasing the total share capital to 111,360,400 shares[7]. - The total number of shares held by major shareholders increased from 38,311,223 to 77,493,974, representing a 102.5% increase[92]. - The total shareholding of the top ten shareholders is 69.60%[92]. - The company has a total of 11,902 shareholders as of the reporting period[89]. Business Operations and Strategy - The company has expanded its product offerings to include feed additives, feed, and veterinary drugs, focusing on one-stop solutions for customers[32]. - The company plans to increase sales and promotion of feed products to counteract the decline in mixed feed additive sales due to market conditions[36]. - The company aims to enhance product quality while reducing production costs to expand market share and achieve sustainable growth[33]. - The company plans to focus on increasing the sales and promotion of feed additives, optimizing the sales team, and developing new products to improve profitability[67]. - The company aims to enhance sales of ruminant, poultry, and aquaculture products through targeted sales strategies and technical services[68]. Risks and Challenges - The company faces risks from major animal epidemics and natural disasters that could impact demand for feed and feed additives[69]. - The company faces risks from cyclical fluctuations in the pig farming industry, with potential impacts on product demand and performance due to declining pig prices[70]. - The company has a significant reliance on a dealer model for sales, which poses risks if relationships with dealers are not maintained[71]. Corporate Governance - The company has established a governance structure to protect the interests of minority shareholders against potential control risks from actual controllers[73]. - The company has not experienced significant changes in major risks during the reporting period[73]. - The company has not reported any changes due to accounting policy adjustments or prior period error corrections in the current period[134]. Research and Development - Research and development expenses increased by 24.56% to ¥5,210,733.62, reflecting the company's commitment to innovation[46]. - The company has been recognized as a "National High-tech Enterprise" and has received "Specialized, Refined, Characteristic, and Innovative" certification[34][35]. Legal and Compliance - The company has no significant litigation or arbitration matters during the reporting period[77]. - The company has no instances of shareholders or related parties occupying or transferring company funds, assets, or other resources[78].

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY -3,006,966.31, representing a decrease of 133.65% year-over-year[10] - Operating revenue for Q1 2023 was CNY 29,231,472.90, down 17.64% from CNY 35,493,365.06 in the same period last year[10] - Total operating revenue for Q1 2023 was CNY 29,231,472.90, a decrease of 17.5% compared to CNY 35,493,365.06 in Q1 2022[38] - Total operating costs increased to CNY 33,443,593.46 in Q1 2023, up 22.5% from CNY 27,336,812.67 in Q1 2022[39] - Net profit for Q1 2023 was a loss of CNY 3,006,966.31, compared to a net profit of CNY 8,936,436.40 in Q1 2022[40] - The company's earnings per share (EPS) for Q1 2023 was -0.05, down from 0.22 in Q1 2022[40] - The total comprehensive income amounted to -2,478,079.04 yuan, compared to 9,577,473.26 yuan in the previous year[43] - Basic and diluted earnings per share were both -0.04 yuan, down from 0.23 yuan year-over-year[43] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 433,954,356.85, a slight increase of 0.15% compared to the end of 2022[10] - The company's asset-liability ratio increased slightly to 18.16% for consolidated figures, compared to 17.34% at the end of 2022[10] - Total liabilities increased to CNY 78,784,432.27 from CNY 75,138,629.71, reflecting a rise of 3.5%[32] - Short-term borrowings rose significantly to CNY 31,000,000.00 from CNY 17,006,572.23, an increase of 82.2%[31] - Total equity decreased to CNY 355,169,924.58 from CNY 358,178,557.34, a decline of 0.6%[32] - Total liabilities increased to CNY 78,203,703.16 in 2023 from CNY 74,808,715.29 in 2022, reflecting a growth of 5.5%[36] - Total equity decreased to CNY 356,528,086.24 in 2023 from CNY 359,006,165.28 in 2022, a decline of 0.7%[36] Cash Flow - The company's cash flow from operating activities improved by 34.69%, reaching CNY -7,646,015.20 compared to CNY -11,707,731.93 in Q1 2022[10] - Cash inflows from operating activities were 37,289,256.27 yuan, an increase from 27,325,217.10 yuan in the same period last year[44] - Cash outflows from operating activities totaled 44,935,271.47 yuan, compared to 39,032,949.03 yuan in the previous year[46] - The net cash flow from operating activities was -7,646,015.20 yuan, an improvement from -11,707,731.93 yuan year-over-year[46] - Cash outflows for investing activities were 16,552,276.64 yuan, significantly higher than 4,675,328.42 yuan in the previous year[46] - Cash inflows from financing activities increased to 51,000,000.00 yuan from 40,000,000.00 yuan year-over-year[46] - The net cash flow from financing activities was 13,513,480.54 yuan, down from 19,625,773.23 yuan in the previous year[46] - The ending cash and cash equivalents balance was 34,428,100.42 yuan, a decrease from 40,192,157.50 yuan year-over-year[46] - The company reported a net decrease in cash and cash equivalents of -10,684,811.30 yuan compared to an increase of 3,242,712.88 yuan in the previous year[46] Shareholder Information - The number of ordinary shareholders as of the report date was 12,721[18] - The largest shareholder, Yan Hejing, holds 47.58% of the total shares, amounting to 26,623,000 shares[19] - The company reported a total of 38,691,082 shares held by the top ten shareholders, representing 69.14% of total shares[21] - The company has no significant changes in shareholder relationships among the top ten shareholders[21] - The company has not conducted any share buybacks during the reporting period[24] Operational Highlights - The company plans to focus on market expansion and new product development in the upcoming quarters[34] - Research and development expenses for Q1 2023 were CNY 2,464,389.29, slightly up from CNY 2,408,734.34 in Q1 2022[39] - The company reported other income of CNY 969,079.63 in Q1 2023, down from CNY 1,472,501.74 in Q1 2022[39] - The company experienced a credit impairment loss of CNY 246,158.06 in Q1 2023, compared to CNY 30.50 in Q1 2022[39] Legal and Compliance - The company has a commitment to fulfill disclosed promises without any overdue situations during the reporting period[25] - The company has not engaged in any litigation or arbitration matters during the reporting period[24] - The company has not provided any external guarantees or loans during the reporting period[24] - The company has not been subject to any investigations or penalties during the reporting period[24]

Company Overview - Shanxi Dayu Biological successfully listed on the Beijing Stock Exchange on May 18, 2022, after receiving approval for public stock issuance from the China Securities Regulatory Commission on April 21, 2022[5]. - The company was awarded the "Enterprise Technology Innovation Award" by the Shanxi Provincial Government for its contributions to scientific and technological progress in 2021[6]. - Shanxi Dayu Biological passed the high-tech enterprise re-examination on December 12, 2022, with certificate number GR202214000436[7]. - The company has been recognized as a high-tech enterprise since December 2016, benefiting from a 15% corporate income tax rate and additional deductions for eligible R&D expenses[14]. - The company has been recognized as a "National High-tech Enterprise" and has received various certifications for its technological advancements[44]. Financial Performance - The company's operating revenue for 2022 was ¥156,983,059.01, a decrease of 12.28% compared to ¥178,959,666.55 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥18,147,189.57, down 48.24% from ¥35,058,919.43 in 2021[28]. - The gross profit margin decreased to 43.80% in 2022 from 48.31% in 2021[28]. - Total assets increased by 46.14% to ¥433,317,187.05 in 2022, compared to ¥296,502,885.46 in 2021[30]. - The company's debt-to-asset ratio (consolidated) improved to 17.34% in 2022 from 28.08% in 2021[30]. - The net cash flow from operating activities was ¥26,602,938.13, a decline of 53.59% from ¥57,326,692.74 in 2021[33]. - The company reported a basic earnings per share of ¥0.37 in 2022, a decrease of 56.98% from ¥0.86 in 2021[28]. - The company achieved revenue of 156.98 million yuan, a year-on-year decrease of 12.28%, and net profit attributable to shareholders was 18.15 million yuan, down 48.24% compared to the previous year[46]. Market and Industry Risks - The company faces risks from major animal epidemics and natural disasters, which could impact demand for feed and feed additives due to reduced livestock populations[13]. - The domestic pig farming industry experiences cyclical fluctuations, affecting the supply and price of pigs, which in turn influences the demand for the company's products[13]. - The company faces risks related to the cyclical nature of pig inventory and prices, which may affect operational performance due to fluctuations in the downstream farming industry[14]. - The company faces risks from the ongoing low prices of live pigs and the recurring African swine fever epidemic, which could adversely affect business development[101]. - The company acknowledges the cyclical nature of the pig farming industry, which may lead to fluctuations in operating performance due to supply-demand imbalances[103]. Sales and Distribution - The company primarily operates through a distribution model, with a significant portion of sales coming from distributors, which poses risks related to maintaining stable relationships with them[14]. - The company's main product areas are concentrated in provinces such as Hebei, Henan, Shandong, Shanxi, Liaoning, Anhui, and Shaanxi, primarily serving small to medium-sized farming clients[14]. - The company has developed a direct sales model since 2019, targeting small to medium-sized clients, which may face challenges in market expansion[14]. - The company established a new sales team targeting large and group customers to enhance direct sales efforts[46]. - The company's main business revenue for 2022 was CNY 156,983,059.01, with sales through distributors accounting for CNY 95,897,377.73, representing 61.09% of total revenue[89]. Research and Development - The company focuses on the research and development of feed additives, including micro-ecological agents and feed enzymes, to meet diverse customer needs[42]. - The company's research and development expenses rose by 18.99% to 10.48 million yuan, reflecting a commitment to innovation[56]. - The total number of R&D personnel increased from 44 to 51, with R&D personnel now accounting for 11.78% of total employees[82]. - The company has a total of 31 patents, including 12 invention patents[83]. - The company is in the pilot stage for several R&D projects aimed at enhancing product functionality and cost efficiency, such as high-temperature glucose oxidase and anti-diarrheal functional bacteria[84]. Corporate Governance - The company’s actual controllers, Yan Heping and Peng Shuiyuan, have significant influence over major operational decisions, which may affect minority shareholders' interests[15]. - The company has implemented measures to stabilize its stock price, including commitments from actual controllers to increase their holdings under specific conditions[138]. - The company has established new corporate governance systems during the year[191]. - The company maintained strict adherence to laws and regulations, ensuring equal rights for all shareholders, particularly minority shareholders[193]. - The company’s internal governance structure operated effectively, fulfilling its responsibilities without any major deficiencies[194]. Share Repurchase and Stock Management - The company has established a share repurchase plan to enhance its incentive mechanism and promote sustainable development, approved by the board on July 22, 2022[124]. - The company plans to repurchase between 279,800 and 559,600 shares, representing 0.50% to 1.00% of the total share capital[127]. - The maximum repurchase price is set at 10 CNY per share, with the average price over the last 30 trading days being 9.43 CNY[126]. - The actual repurchase quantity reached 559,600 shares, which is 100% of the upper limit of the planned repurchase[130]. - The total amount paid for the repurchased shares was 5,105,602.57 CNY, accounting for 91.2366% of the maximum planned repurchase fund[130]. Future Plans and Strategies - The company aims to expand its market share by enhancing product quality and reducing production costs[43]. - The company plans to diversify its product line and reduce reliance on single products to mitigate market risks[103]. - The company will enhance service standards and technical support to improve customer satisfaction and build long-term cooperative relationships[99]. - In 2023, the company will focus on key products, vigorously develop new products, and promote deep integration of products[98]. - The company aims to enhance its market competitiveness and profitability through favorable national industrial policies and trends[142].

Financial Performance - The company's total revenue for 2022 was CNY 156,983,059.01, a decrease of 12.28% compared to the previous year[4] - Net profit attributable to shareholders was CNY 18,639,103.88, down 46.83% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 11,083,899.76, a decline of 61.20% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period reached CNY 431,797,051.00, an increase of 45.63% year-on-year[5] - Shareholders' equity attributable to the company was CNY 358,670,471.65, up 68.19% from the beginning of the period[5] - The increase in total assets and equity was primarily due to the issuance of shares to unspecified qualified investors and an increase in undistributed profits[6] Challenges and Market Conditions - The company faced challenges due to domestic pandemic restrictions affecting marketing activities and logistics, leading to lower revenue expectations[6] - The decline in revenue was also influenced by low pork prices and significant increases in feed raw material costs, resulting in reduced purchasing desire from farmers[6] Future Plans and Cautions - The company plans to enhance its marketing system and strengthen brand image to improve competitiveness and return better results to investors[5] - The company warns that the financial data presented is preliminary and unaudited, urging investors to be cautious[7]

Financial Performance - The company's net profit attributable to shareholders for the reporting period is expected to be 18.64 million yuan, a decrease of 46.83% compared to 35.06 million yuan in the same period last year[4]. - The decline in performance is primarily due to the impact of pandemic lockdowns and a slump in pork prices, leading to reduced operating income[5]. Cost Factors - Increased prices of feed raw materials, such as soybean meal, have resulted in a decrease in the procurement of high-margin micro-ecological preparation products, while lower-margin feed products saw an increase in procurement[6]. - The increase in sales and management personnel has led to higher employee compensation costs[6]. Cautionary Notes - The financial data presented is preliminary and has not been audited by an accounting firm, thus investors are advised to exercise caution[7].

Financial Performance - Net profit attributable to shareholders decreased by 20.80% to CNY 11,731,517.27 for the year-to-date period[15] - Operating income for the year-to-date period decreased by 13.63% to CNY 96,125,595.93 compared to the same period last year[15] - Cash flow from operating activities decreased by 47.85% to CNY 9,041,300.56 compared to the same period last year[15] - Operating income for Q3 2022 increased by 8.95% to CNY 36,725,823.02 compared to Q3 2021[15] - Total operating revenue for Q3 2022 reached ¥36,725,823.02, an increase from ¥33,708,486.57 in Q3 2021, representing an increase of approximately 8.9% year-over-year[49] - Net profit for Q3 2022 was ¥3,887,300.91, up from ¥3,360,055.59 in Q3 2021, reflecting a growth of approximately 15.7% year-over-year[51] - The company’s total comprehensive income for the first nine months of 2022 was CNY 13,238,039, compared to CNY 15,830,795 in the same period of 2021[56] Assets and Liabilities - Total assets increased by 36.94% to CNY 406,038,834.29 compared to the end of the previous year[15] - Total current assets increased to CNY 131,543,220.47 as of September 30, 2022, up from CNY 86,677,798.07 on December 31, 2021, representing a growth of approximately 51.7%[41] - Non-current assets totaled CNY 274,495,613.82 as of September 30, 2022, up from CNY 209,825,087.39 on December 31, 2021, reflecting a growth of approximately 30.8%[42] - Total liabilities decreased to CNY 51,117,193.01 as of September 30, 2022, down from CNY 83,252,251.30 on December 31, 2021, a reduction of approximately 38.6%[43] - The total liabilities amounted to ¥50,769,042.72, while total equity reached ¥357,672,867.35, indicating a strong equity position relative to liabilities[47] Shareholder Information - The total number of ordinary shares at the end of the period was 55,960,000, with 14,228 shareholders[24] - The largest shareholder, Yan Heping, holds 26,623,000 shares, representing 47.58% of total shares[26] - The company plans to repurchase between 279,800 and 559,600 shares at a maximum price of 10 CNY per share, with a total estimated repurchase fund of 2.798 million to 5.596 million CNY[34] - As of September 30, 2022, the company had repurchased 213,000 shares, accounting for 0.3806% of total shares, with a total expenditure of 1,949,402.82 CNY[35] Cash Flow and Investments - Cash flow from operating activities for the first nine months of 2022 was CNY 9,041,301, a decrease of 48% from CNY 17,338,376 in 2021[57] - Total cash and cash equivalents at the end of Q3 2022 amounted to CNY 75,311,962, up from CNY 19,519,772 at the end of Q3 2021[58] - The company raised CNY 136,750,000 through investment in the first nine months of 2022[58] - Cash outflow from investing activities totaled $79,898,275.92, significantly higher than $25,126,878.71 in the prior period[60] - Cash used for the acquisition of fixed assets was $79,598,275.92, compared to $23,926,878.71, indicating a significant increase in capital expenditures[60] Government Support and Subsidies - The company received a government listing reward of CNY 1,500,000, contributing to an increase in other income[19] - The company received government subsidies closely related to its business totaling 5,194,733.78 CNY[22] Research and Development - Research and development expenses for Q3 2022 were ¥2,978,783.04, compared to ¥2,287,664.89 in Q3 2021, showing an increase of approximately 30.2% year-over-year[50] - Research and development expenses for the first nine months of 2022 totaled CNY 7,162,009, an increase of 10% compared to CNY 6,484,226 in 2021[53] Inventory and Contract Liabilities - Inventory increased by 30.98% to CNY 2,878,000 compared to the end of the previous year due to market demand[17] - The company reported a 389.71% increase in contract liabilities, attributed to new product offerings and advance payments from direct sales customers[18] - Inventory rose to CNY 28,685,144.99 as of September 30, 2022, compared to CNY 21,900,686.36 on December 31, 2021, indicating an increase of about 30.9%[41] Legal and Financial Commitments - The company has no outstanding commitments or overdue obligations related to disclosed commitments during the reporting period[36] - There were no significant legal disputes or external guarantees during the reporting period[30] - The company has cleared its bank loans and does not have any assets under mortgage or pledge as of the reporting period end[37]